Company
Denteric
First - in - class therapeutic for treating chronic inflammation
- Business model
- B2B
- Customers
- patients with severe or refractory disease
Claim, correct or request removal
Record updated 28 September 2026
About
Developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis)
Products
- Web
- GPV381
Loading relationship preview